Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Obese Children

被引:20
|
作者
Hecht, Lior [1 ,2 ]
Weiss, Ram [1 ,2 ,3 ]
机构
[1] Hadassah Hebrew Univ Sch Med, Dept Human Metab & Nutr, IL-91120 Jerusalem, Israel
[2] Hadassah Hebrew Univ Sch Med, Sect Pediat Endocrinol, IL-91120 Jerusalem, Israel
[3] Hadassah Hebrew Univ Sch Med, Dept Human Metab & Nutr, Braun Sch Publ Hlth, IL-91120 Jerusalem, Israel
关键词
Nonalcoholic fatty liver disease (NAFLD); Insulin resistance; Insulin clearance; Type; 2; diabetes; INSULIN-RESISTANCE; METABOLIC SYNDROME; GLUCOSE-TOLERANCE; HEPATIC STEATOSIS; SKELETAL-MUSCLE; GUT MICROBIOTA; ADOLESCENTS; PREVALENCE; ADIPONECTIN; ASSOCIATION;
D O I
10.1007/s11892-013-0448-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is commonly found in adults and adolescents with type 2 diabetes (T2DM). The cause-effect relations of these 2 conditions are complex and it is difficult to decipher whether one drives the other or vice versa. Genetic predispositions, along with obesity, are probably shared culprits of both. NAFLD may precede the diagnosis of diabetes and play a critical role of driving its development by way of increasing hepatic and whole body insulin resistance. On the other hand, T2DM is associated with hyperinsulinemia, a resistance to some of the effects of gut derived peptides and increased systemic free fatty acids, that can all promote hepatic lipid deposition. Thus, each condition may promote the development of the other and their mutual presence creates a vicious cycle. Upon studying this complex interplay from another angle, reduction of liver fat significantly improves glucose metabolism in patients with T2DM highlighting the tight pathophysiological link between them.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood
    Bardugo, Aya
    Bendor, Cole D.
    Zucker, Inbar
    Lutski, Miri
    Cukierman-Yaffe, Tali
    Derazne, Estela
    Mosenzon, Ofri
    Tzur, Dorit
    Beer, Zivan
    Pinhas-Hamiel, Orit
    Ben-Ami, Michal
    Fishman, Boris
    Shor, Dana Ben-Ami
    Raz, Itamar
    Afek, Arnon
    Gerstein, Hertzel C.
    Haring, Hans-Ulrich
    Tirosh, Amir
    Levi, Zohar
    Twig, Gilad
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (01): : E34 - E44
  • [22] Nonalcoholic Fatty Liver Disease and Endothelial Dysfunction in Patients With Type 2 Diabetes
    Shin, Jang Yel
    Lim, Jung Soo
    Lee, Mi Young
    Chung, Choon Hee
    DIABETES, 2013, 62 : A119 - A119
  • [23] Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship
    Muzica, Cristina M.
    Sfarti, Catalin
    Trifan, Anca
    Zenovia, Sebastian
    Cuciureanu, Tudor
    Nastasa, Robert
    Huiban, Laura
    Cojocariu, Camelia
    Singeap, Ana-Maria
    Girleanu, Irina
    Chiriac, Stefan
    Stanciu, Carol
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 2020
  • [24] Effect of nateglinide on nonalcoholic fatty liver disease as a complication in type 2 diabetes
    Matsuura, Kenichi
    Mori, Yutaka
    Itoh, Yohta
    Tajima, Naoko
    DIABETES, 2007, 56 : A555 - A555
  • [25] Decreased prevalence of nonalcoholic fatty liver disease in black obese children
    Louthan, MV
    Theriot, JA
    Zimmerman, E
    Stutts, JT
    McClain, CJ
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2005, 41 (04): : 426 - 429
  • [26] Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes
    Birkenfeld, Andreas L.
    Shulman, Gerald I.
    HEPATOLOGY, 2014, 59 (02) : 713 - 723
  • [27] Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus
    Fan, Yanbo
    Xiong, Wei
    Li, Jingjing
    Hu, Aimin
    He, Zhiwei
    Zhang, Jiawen
    Zhou, Guoyun
    Yin, Qiang
    PHARMACEUTICAL BIOLOGY, 2018, 56 (01) : 567 - 572
  • [28] Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
    Chiara Saponaro
    Melania Gaggini
    Amalia Gastaldelli
    Current Diabetes Reports, 2015, 15
  • [29] Type 2 diabetes, congestive heart failure and nonalcoholic fatty liver disease
    Maechler, Maximilian
    Vonbank, Alexander
    Larcher, Barbara
    Mader, Arthur
    Sprenger, Lukas
    Leiherer, Andreas
    Zanolin-Purin, Daniela
    Muendlein, Axel
    Drexel, Heinz
    Saely, Christoph H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S354 - S354
  • [30] Dapagliflozin Therapy in Type 2 Diabetes Patients with nonalcoholic Fatty Liver Disease
    Kahl, S.
    DIABETOLOGE, 2018, 14 (07): : 506 - 508